Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933785 | 0.86 | TTK (0.68) | TTKPIK3CGPIK3CDPIK3CALRRK2 | |
| SCHEMBL1934192 | 0.83 | TTK (0.64) | TTKPIK3CGPIK3CDPIK3CALRRK2 | |
| SCHEMBL16306665 | 0.82 | TTK (0.63) | TTKPIK3CGPIK3CDPIK3CALRRK2 | |
| SCHEMBL1933195 | 0.82 | TTK (0.74) | TTKPIK3CGPIK3CDPIK3CALRRK2 | |
| SCHEMBL1932155 | 0.82 | PIK3CG (0.70) | TTKPIK3CGPIK3CDPIK3CAFYN | |
| SCHEMBL3082694 | 0.82 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3091846 | 0.82 | PIK3CG (0.80) | TTKPIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL15455914 | 0.82 | TTK (0.59) | TTKPIK3CGPIK3CDPIK3CAJAK1 | |
| SCHEMBL2187962 | 0.81 | PIK3CG (0.70) | TTKPIK3CGPIK3CDPIK3CALRRK2 | |
| SCHEMBL12507204 | 0.79 | PIK3CG (0.67) | TTKPIK3CGPIK3CDPIK3CABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | claimed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | claimed |
| EP-2343295-A1 | Triazolopyridine derivates | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | claimed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | claimed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2343295-A1 | Triazolopyridine derivates | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343295-A1 | Triazolopyridine derivates | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | TTBK1, BUB1, TTK | TTK 3/4885PIK3CG 718/4885PIK3CD 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.